

The Impact of Industry-Sponsored Clinical Trials



Vermont

91 Clinical trials	1,106 Clinical trial participants	\$12.2 Million Investments at clinical trial sites	\$30 Million Total economic impact of clinical trial sites
------------------------------	---	--	--

The biopharmaceutical industry brings profound value to patients through new treatments and cures for society's most devastating and costly diseases and conditions, providing millions of patients with treatment options they would not otherwise have. Since 2000, PhRMA member companies have invested over \$800 billion in the research and development of new treatments and cures, including an estimated \$71.4 billion in 2017 alone.

Developing innovative new medicines is a complex process taking an average 10-15 years. Less than 12 percent of candidate medicines that make it into clinical trials will be approved by the U.S. Food and Drug Administration. Clinical trials are the most time- and resource-intensive part of the research and development process for a new medicine, and biopharmaceutical manufacturers support and conduct the majority of this important work. Yet, without clinical trials, new medicines could not be approved and—most importantly—made available to patients who need them.

Frequently Asked Questions

Which clinical trials are included?

All industry-sponsored clinical trials of a potential new medicine that were active at any point in 2017. This includes Phase I through Phase IV trials.

What do investments at clinical trial sites include?

The overall economic impact of the biopharmaceutical industry on the U.S. economy is substantial. This number reflects the direct investments made by biopharmaceutical manufacturers to identify and operate clinical trial sites; hire staff and contractors; recruit, retain and treat participants; and conduct clinical trial protocols and activities, including monitoring research sites.

What is not measured?

These estimates focus solely on the investments made at clinical trial sites by America's biopharmaceutical companies and do not capture all of the trial-wide work that occurs across sites, companies' substantial investments in basic and preclinical research, or the nationwide economic impact associated with the non-R&D activities of the industry. Altogether, the industry supports more than 4 million U.S. jobs and \$1.3 trillion in annual economic output.

Source: TEconomy Partners, *Biopharmaceutical Industry-Sponsored Clinical Trials: Growing State Economies*, April 2019.